Impact of CaRD therapy on serum IgM and hematocrit levels. (A) Serum IgM and (B) hematocrit levels during the course of protocol therapy including induction cycles (C1-C6), interphase between induction and maintenance therapy (INT), maintenance cycles (M1-M8), and end of treatment (EOT) for all 31 patients who received CaRD. The black line and darker and lighter shaded areas represent the median, interquartile, and range of datapoints, respectively.